Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan
WASHINGTON (Reuters) - About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's (N:ABBV) planned billion purchase of Botox maker Allergan Plc (N:AGN).
The combination of two of the world's biggest pharmaceutical companies, which was announced in June, would feature a portfolio that includes the world's top-selling medicine - AbbVie's rheumatoid arthritis drug Humira - as well as its cancer drugs and Allergan's blockbuster wrinkle treatment, Botox, and big-selling dry eye drug Restasis.
In the letter seen by Reuters, Consumer Action ...